A new experimental antibiotic Zaynich has shown 97% effectiveness in fighting drug-resistant infections, offering hope ...
Mumbai: Wockhardt has announced that Zaynich (Zidebactam/Cefepime, WCK 5222) demonstrated over 97 percent clinical efficacy ...
Shares of Wockhardt were in high demand on Monday after the company said that its drug Zaynich has achieved over 97 per cent ...
What drove Wockhardt share price today? Wockhardt share price jumped in a weak market after it announced through an exchange ...
Urinary tract infections (UTIs) are recognized as the second most common medical condition, following respiratory infections. Despite the availability of numerous efficacious antibiotics for the ...